Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing?

Por Reni, Michele
Publicado em 2010

Adjuvant treatment in biliary tract cancer: To treat or not to treat?

Por Cereda, Stefano, Belli, Carmen, Reni, Michele
Publicado em 2012

Role of taxanes in pancreatic cancer

Por Belli, Carmen, Cereda, Stefano, Reni, Michele
Publicado em 2012

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

Por Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Publicado no Onco Targets Ther (2017)

Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a prel...

Por Venturini, Massimo, Sallemi, Claudio, Agostini, Giulia, Marra, Paolo, Cereda, Stefano, Reni, Michele, Aldrighetti, Luca, De Cobelli, Francesco, Del Maschio, Alessandro
Publicado no Br J Radiol (2016)

Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma

Por Brandes, Alba A., Nicolardi, Linda, Tosoni, Alicia, Gardiman, Marina, Iuzzolino, Paolo, Ghimenton, Claudio, Reni, Michele, Rotilio, Antonino, Sotti, Guido, Ermani, Mario
Publicado em 2006

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

Por De Monte, Lucia, Reni, Michele, Tassi, Elena, Clavenna, Daniela, Papa, Ilenia, Recalde, Helios, Braga, Marco, Di Carlo, Valerio, Doglioni, Claudio, Protti, Maria Pia
Publicado em 2011

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

Por Vaccaro, Vanja, Sperduti, Isabella, Vari, Sabrina, Bria, Emilio, Melisi, Davide, Garufi, Carlo, Nuzzo, Carmen, Scarpa, Aldo, Tortora, Giampaolo, Cognetti, Francesco, Reni, Michele, Milella, Michele
Publicado no World J Gastroenterol (2015)

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma

Por Reni, Michele, Balzano, Gianpaolo, Zanon, Silvia, Passoni, Paolo, Nicoletti, Roberto, Arcidiacono, Paolo Giorgio, Pepe, Gino, Doglioni, Claudio, Fugazza, Clara, Ceraulo, Domenica, Falconi, Massimo, Gianni, Luca
Publicado no Br J Cancer (2016)

Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination

Por Ferreri, Andrés J. M., Licata, Giada, Foppoli, Marco, Corazzelli, Gaetano, Zucca, Emanuele, Stelitano, Caterina, Zaja, Francesco, Fava, Sergio, Paolini, Rossella, Franzin, Alberto, Politi, Letterio S., Ponzoni, Maurilio, Reni, Michele
Publicado em 2011

Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study

Por Balzano, Gianpaolo, Dugnani, Erica, Gandolfi, Alessandra, Scavini, Marina, Pasquale, Valentina, Aleotti, Francesca, Liberati, Daniela, Di Terlizzi, Gaetano, Petrella, Giovanna, Reni, Michele, Doglioni, Claudio, Bosi, Emanuele, Falconi, Massimo, Piemonti, Lorenzo
Publicado no PLoS One (2016)

MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?

Por Brunetti, Oronzo, Russo, Antonio, Scarpa, Aldo, Santini, Daniele, Reni, Michele, Bittoni, Alessandro, Azzariti, Amalia, Aprile, Giuseppe, Delcuratolo, Sabina, Signorile, Michele, Gnoni, Antonio, Palermo, Loredana, Lorusso, Vito, Cascinu, Stefano, Silvestris, Nicola
Publicado no Oncotarget (2015)

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

Por Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Caserta, Claudia, Fabi, Alessandra, Clavarezza, Matteo, Maiello, Evaristo, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Proietti, Emanuela, Agati, Raffaele, Eusebi, Vincenzo, Franceschi, Enrico
Publicado no Neuro Oncol (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Por Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Ma, Wen Wee, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Li, Jack Shiansong, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Publicado no Br J Cancer (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Por Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Wee Ma, Wen, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Shiansong Li, Jack, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Publicado no Br J Cancer (2016)

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)

Por Annemans, Lieven, Aymé, Ségolène, Le Cam, Yann, Facey, Karen, Gunther, Penilla, Nicod, Elena, Reni, Michele, Roux, Jean-Louis, Schlander, Michael, Taylor, David, Tomino, Carlo, Torrent-Farnell, Josep, Upadhyaya, Sheela, Hutchings, Adam, Le Dez, Lugdivine
Publicado no Orphanet J Rare Dis (2017)

AT-11 FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM

Por Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Clavarezza, Matteo, Maiello, Evaristo, Cartenì, Giacomo, Rosti, Giovanni, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Agati, Raffaele, Eusebi, Vincenzo, Galli, Anna, Doria, Simona, Franceschi, Enrico
Publicado em 2014

NI-26 COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.

Por Franceschi, Enrico, Agati, Raffaele, Finocchiaro, Gaetano, Zagonel, Vittorina, Fabi, Alessandra, Reni, Michele, Caserta, Claudia, Maiello, Evaristo, Cartenì, Giacomo, Clavarezza, Matteo, Rosti, Giovanni, Eoli, Marica, Lombardi, Giuseppe, Bacci, Antonella, Monteforte, Marta, Doria, Simona, Galli, Anna, Brandes, Alba A.
Publicado em 2014

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Por Von Hoff, Daniel D., Ervin, Thomas, Arena, Francis P., Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A., Ma, Wen Wee, Saleh, Mansoor N., Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K., Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F.
Publicado no N Engl J Med (2013)

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)

Por Baumert, Brigitta G., Hegi, Monika E., van den Bent, Martin J., von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A., Kantor, Guy, Taphoorn, Martin J.B., Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M., Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E., Feuvret, Loic, Reijneveld, Jaap C., Chinot, Olivier, Gijtenbeek, Johanna M. M., Rossiter, John P., Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M., Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A., Rees, Jeremy, Lacombe, Denis, Mason, Warren P., Stupp, Roger
Publicado no Lancet Oncol (2016)